US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kailera Therapeutics

14.85

+0.00500.03%

Volume:451.06K

Turnover:6.66M

Market Cap:1.92B

PE:-6.59

High:14.98

Open:14.58

Low:14.51

Close:14.84

52wk High:28.23

52wk Low:14.51

Shares:129.54M

Float Shares:44.92M

Volume Ratio:0.64

T/O Rate:1.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2543

EPS(LYR):-7,819.9811

ROE:-36.90%

ROA:-22.73%

PB:1.72

PE(LYR):0.00

Loading ...

Overview Company News Filings

RTW Investments buys 500,000 Kailera Therapeutics shares for $8 million

Stock Track | Kailera Therapeutics Soars 5.24% in Pre-Market on Insider Buying Spree

Massive Insider Buying Spree Signals Surging Confidence in Kailera Therapeutics

Kailera director Adam Koppel reports acquiring 1,562,500 shares for $25 million

Bain Capital Life Sciences Investors acquires 1,562,500 Kailera Therapeutics shares for $25 million

Kailera director Andrew Kaplan acquires 8,398,438 shares valued at $134.4 million

Kailera Therapeutics Closes Initial Public Offering

MT Newswires Live

Stock Track | Kailera Therapeutics Plummets 5.35% Intraday on Corporate Governance Changes

Kailera Therapeutics adopts amended bylaws setting new stockholder proposal, director nomination rules

Kailera Therapeutics closes IPO, raises USD 718.8 million at USD 16 share

Kailera Stock (KLRA) Rockets 68% after IPO as It Chases $76B Obesity Opportunity

Weight-Loss Drug Developer Kailera Therapeutics Soars Over 50% in U.S. Market Debut

Stock Track | Kailera Therapeutics Soars 62.50% in Intraday Trading on Strong Nasdaq Debut After $625 Million IPO

Kailera Therapeutics Shares Open for Trading at $26 in Nasdaq Debut VS U.S. IPO Price of $16 Each

THOMSON REUTERS

BUZZ-Obesity drug developer Kailera on track for Nasdaq debut above offer price

Weight-Loss Drug Contender Kailera Therapeutics (KLRA.US) Raises $625 Million in Largest US Biotech IPO Since 2021, Set for Nasdaq Debut

Kailera Therapeutics 39.06M share IPO priced at $16.00

BRIEF-Kailera Therapeutics Announces Pricing Of Initial Public Offering

Kailera Therapeutics Announces Pricing of Initial Public Offering

Kailera Therapeutics Sets IPO Price Range at $14-$16 Per Share, Aims for Nasdaq Listing This Friday

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/KLRA/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KLRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","market":"US","secType":"STK","nameCN":"Kailera Therapeutics","latestPrice":14.845,"timestamp":1789069477607,"preClose":14.84,"halted":0,"volume":451062,"delay":0,"changeRate":0.0003369272237197292,"floatShares":44921899,"shares":129537300,"eps":-2.254252,"marketStatus":"Trading","change":0.005,"latestTime":"09-10 15:44:46 EDT","open":14.58,"high":14.975,"low":14.51,"amount":6659578.60164,"amplitude":0.031334,"askPrice":14.85,"askSize":39,"bidPrice":14.83,"bidSize":477,"shortable":0,"etf":0,"ttmEps":-2.254252,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789070400000},"marketStatusCode":2,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":14.84,"preHourTrading":{"tag":"盘前","latestPrice":14.56,"preClose":14.84,"latestTime":"09:29 EDT","volume":416,"amount":6075.959968,"timestamp":1789046999999,"change":-0.28,"changeRate":-0.018868,"amplitude":0.009434},"postHourTrading":{"tag":"盘后","latestPrice":14.43,"preClose":14.84,"latestTime":"19:51 EDT","volume":14865,"amount":219893.46,"timestamp":1788997880189,"change":-0.41,"changeRate":-0.027628,"amplitude":0.027628},"volumeRatio":0.642865},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","floatShares":44921899,"roa":"-22.73%","roe":"-36.90%","lyrEps":-7819.9811,"volumeRatio":0.642865,"shares":129537300,"dividePrice":0,"high":14.975,"amplitude":0.031334,"preClose":14.84,"low":14.51,"week52Low":14.51,"pbRate":"1.72","week52High":28.2271,"institutionHeld":0,"latestPrice":14.845,"committee":0.848837,"eps":-2.254252,"divideRate":0,"volume":451062,"delay":0,"ttmEps":-2.254252,"open":14.58,"prevYearClose":16,"prevWeekClose":16.23,"prevMonthClose":15.4,"prevQuarterClose":22.03,"fiveDayClose":15.85,"twentyDayClose":18.59,"sixtyDayClose":19.67},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"KLRA","fiscalQuarterEnding":"2026/06","expectedEps":-0.74,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-1.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1783483200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRA","date":"2026-09-09","current":-6.585333,"percent":0.939394,"low":-21.871461,"twenty":-19.474134,"median":-13.590258,"eighty":-10.452335,"high":-6.832762,"avg":-14.47641,"sd":4.702358,"marketCap":2130045596},"quantilePoints":[{"date":"2026-04-17","current":-12.669466,"twenty":-12.511098,"median":-12.273546,"eighty":-12.035993,"marketCap":1887180368},{"date":"2026-04-24","current":-20.824025,"twenty":-20.917019,"median":-20.433783,"eighty":-14.17085,"marketCap":3101842710},{"date":"2026-05-01","current":-21.741015,"twenty":-21.413894,"median":-20.305085,"eighty":-18.829635,"marketCap":3238432850},{"date":"2026-05-08","current":-19.540824,"twenty":-21.576784,"median":-20.824025,"eighty":-19.524523,"marketCap":2910703445},{"date":"2026-05-15","current":-18.697273,"twenty":-21.521865,"median":-20.058623,"eighty":-18.676401,"marketCap":2785052251},{"date":"2026-05-22","current":-18.332024,"twenty":-21.403595,"median":-19.540824,"eighty":-18.304195,"marketCap":2730646579},{"date":"2026-05-29","current":-19.949555,"twenty":-21.097481,"median":-19.520448,"eighty":-18.332024,"marketCap":2971585983},{"date":"2026-06-05","current":-18.253756,"twenty":-20.940268,"median":-19.530636,"eighty":-18.332024,"marketCap":2718988220},{"date":"2026-06-12","current":-16.992777,"twenty":-20.824025,"median":-19.392985,"eighty":-17.13192,"marketCap":2531159115},{"date":"2026-06-18","current":-16.636224,"twenty":-20.511831,"median":-18.758148,"eighty":-17.050173,"marketCap":2478048816},{"date":"2026-06-26","current":-12.75669,"twenty":-20.227867,"median":-18.684228,"eighty":-17.050173,"marketCap":2676825461},{"date":"2026-07-02","current":-12.855483,"twenty":-20.165517,"median":-18.622605,"eighty":-16.764931,"marketCap":2697555958},{"date":"2026-07-10","current":-12.9728,"twenty":-20.033041,"median":-18.410291,"eighty":-15.433812,"marketCap":2722173424},{"date":"2026-07-17","current":-11.311837,"twenty":-19.949555,"median":-18.314631,"eighty":-13.521103,"marketCap":2373641938},{"date":"2026-07-24","current":-10.743775,"twenty":-19.944337,"median":-17.453687,"eighty":-12.859187,"marketCap":2254441579},{"date":"2026-07-31","current":-10.527665,"twenty":-19.923466,"median":-17.13192,"eighty":-12.704356,"marketCap":2209093616},{"date":"2026-08-07","current":-11.651439,"twenty":-19.849563,"median":-17.071044,"eighty":-11.79378,"marketCap":2444903022},{"date":"2026-08-14","current":-7.973035,"twenty":-19.724778,"median":-16.992777,"eighty":-11.573639,"marketCap":2329696857},{"date":"2026-08-21","current":-7.746755,"twenty":-19.603438,"median":-16.640572,"eighty":-11.334065,"marketCap":2263578582},{"date":"2026-08-28","current":-8.221499,"twenty":-19.532674,"median":-16.131833,"eighty":-11.014222,"marketCap":2402297316},{"date":"2026-09-04","current":-6.983615,"twenty":-19.497291,"median":-13.667441,"eighty":-10.594351,"marketCap":2040591460},{"date":"2026-09-09","current":-7.289759,"twenty":-19.474134,"median":-13.590258,"eighty":-10.452335,"marketCap":2130045596}],"updateTime":1789069486801},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLRA\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2629020224","title":"RTW Investments buys 500,000 Kailera Therapeutics shares for $8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629020224","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629020224?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:20","pubTimestamp":1776889245,"startTime":"0","endTime":"0","summary":"RTW Investments reported a larger stake in Kailera Therapeutics, taking beneficial ownership to 10,776,820 common shares.Filing showed purchase of 500,000 shares at USD 16.Roderick Wong, managing partner at RTW Investments, was listed as a reporting beneficial owner.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kailera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL6Kd310:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RTW Investments buys 500,000 Kailera Therapeutics shares for $8 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160047386","title":"Stock Track | Kailera Therapeutics Soars 5.24% in Pre-Market on Insider Buying Spree","url":"https://stock-news.laohu8.com/highlight/detail?id=1160047386","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160047386?lang=en_us&edition=fundamental","pubTime":"2026-04-21 20:44","pubTimestamp":1776775466,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics (KLRA) experienced a significant pre-market surge of 5.24% on Tuesday, indicating heightened investor activity before the opening bell.The sharp upward movement appears to be...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629705962","title":"Massive Insider Buying Spree Signals Surging Confidence in Kailera Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2629705962","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629705962?lang=en_us&edition=fundamental","pubTime":"2026-04-21 10:03","pubTimestamp":1776736981,"startTime":"0","endTime":"0","summary":"New insider activity at Kailera Therapeutics, Inc. ( ($KLRA) ) has taken place on April 20, 2026. Kailera Therapeutics, Inc. has seen a major wave ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/massive-insider-buying-spree-signals-surging-confidence-in-kailera-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/massive-insider-buying-spree-signals-surging-confidence-in-kailera-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA","SHAP.U"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629717667","title":"Kailera director Adam Koppel reports acquiring 1,562,500 shares for $25 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629717667","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629717667?lang=en_us&edition=fundamental","pubTime":"2026-04-21 06:09","pubTimestamp":1776722961,"startTime":"0","endTime":"0","summary":"Adam Koppel, director, reported an increase in indirect ownership of Kailera Therapeutics common stock to 22,583,268 shares.Filing showed acquisition of 1,562,500 shares at USD 16 per share.Report also reflected conversion into common stock of 16,875,000 shares of Series A-1 Preferred Stock.Conversion into common stock of 4,145,768 shares of Series B Preferred Stock was also reported.Koppel reported receipt of a stock option for 38,300 shares with an exercise price of USD 16.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kailera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commissio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL2sh4yf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629714107","title":"Bain Capital Life Sciences Investors acquires 1,562,500 Kailera Therapeutics shares for $25 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629714107","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629714107?lang=en_us&edition=fundamental","pubTime":"2026-04-21 06:02","pubTimestamp":1776722549,"startTime":"0","endTime":"0","summary":"Bain Capital Life Sciences Investors, a 10% owner, reported a sharp increase in its stake in Kailera Therapeutics.Holdings rose to 22,583,268 shares of common stock held indirectly.Filing showed 1,562,500 shares were purchased at USD 16 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kailera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL4ddHgv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629777146","title":"Kailera director Andrew Kaplan acquires 8,398,438 shares valued at $134.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629777146","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629777146?lang=en_us&edition=fundamental","pubTime":"2026-04-21 06:00","pubTimestamp":1776722459,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics director Andrew T. Kaplan reported an increase in beneficial ownership to 26,255,581 shares of common stock held indirectly.Filing also showed acquisition of 8,398,438 shares at USD 16 per share.Kaplan also received stock options for 38,300 shares with an exercise price of USD 16.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kailera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL9J7mN5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Kailera director Andrew Kaplan acquires 8,398,438 shares valued at $134.4 million","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629799417","title":"Kailera Therapeutics Closes Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2629799417","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629799417?lang=en_us&edition=fundamental","pubTime":"2026-04-21 05:05","pubTimestamp":1776719159,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics  said Monday it has closed its initial public offering of about 44.9 million shares, including the exercise in full by the underwriters of an option to buy nearly 5.9 million additional shares, at $16 per share, for gross proceeds of $718.8 million.All of the shares were offered by the company, according to a statement.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KLRA","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109550352","title":"Stock Track | Kailera Therapeutics Plummets 5.35% Intraday on Corporate Governance Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=1109550352","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109550352?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:22","pubTimestamp":1776716549,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics' stock experienced a significant decline of 5.35% during Monday's intraday trading session.The sharp drop followed the company's announcement that it has adopted amended and...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629768777","title":"Kailera Therapeutics adopts amended bylaws setting new stockholder proposal, director nomination rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2629768777","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629768777?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:19","pubTimestamp":1776716378,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics implemented amended and restated bylaws on April 20, 2026 in connection with IPO closing.Bylaws set advance-notice procedures for stockholder proposals at meetings.Changes align bylaws with corporate governance provisions in restated charter, including classified board structure.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kailera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL331r0J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629377528","title":"Kailera Therapeutics closes IPO, raises USD 718.8 million at USD 16 share","url":"https://stock-news.laohu8.com/highlight/detail?id=2629377528","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629377528?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:10","pubTimestamp":1776715839,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics closed initial public offering of 44,921,875 shares of common stock at USD 16 per share.Gross proceeds totaled USD 718.8 million before underwriting discounts, commissions, and offering expenses.Underwriters exercised option in full to purchase 5,859,375 additional shares.Common stock began trading on Nasdaq Global Select Market under ticker KLRA.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL7r1fpP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014005.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BK4588","LU2210150020.SGD","SG9999014039.USD","BK4585","IE00BN0W2W23.USD","LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","SG9999014021.USD","LU2210149790.SGD","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628478627","title":"Kailera Stock (KLRA) Rockets 68% after IPO as It Chases $76B Obesity Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2628478627","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628478627?lang=en_us&edition=fundamental","pubTime":"2026-04-18 02:40","pubTimestamp":1776451218,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics’ ($KLRA) shares soared as high as 68% on Friday following their debut on Nasdaq, with the obesity treatment developer raising ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/kailera-stock-klra-rockets-60-after-ipo-as-it-chases-76b-obesity-opportunity?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/kailera-stock-klra-rockets-60-after-ipo-as-it-chases-76b-obesity-opportunity?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPOS","SPCX","NQmain","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133154965","title":"Weight-Loss Drug Developer Kailera Therapeutics Soars Over 50% in U.S. Market Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=1133154965","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133154965?lang=en_us&edition=fundamental","pubTime":"2026-04-18 01:36","pubTimestamp":1776447386,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics (KLRA.US), a newcomer in the weight-loss drug sector, began trading on the U.S. stock market on Friday, surging more than 50% at the opening to $24.1 per share, compared with its...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","KLRA","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139914760","title":"Stock Track | Kailera Therapeutics Soars 62.50% in Intraday Trading on Strong Nasdaq Debut After $625 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1139914760","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139914760?lang=en_us&edition=fundamental","pubTime":"2026-04-18 01:27","pubTimestamp":1776446849,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics (KLRA) experienced a significant intraday surge, with its stock price soaring 62.50% during Friday's trading session. This movement marks a volatile start for the biotechnology...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628785125","title":"Kailera Therapeutics Shares Open for Trading at $26 in Nasdaq Debut VS U.S. IPO Price of $16 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2628785125","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628785125?lang=en_us&edition=fundamental","pubTime":"2026-04-18 01:25","pubTimestamp":1776446749,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nL4N41016M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628202449","title":"BUZZ-Obesity drug developer Kailera on track for Nasdaq debut above offer price","url":"https://stock-news.laohu8.com/highlight/detail?id=2628202449","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628202449?lang=en_us&edition=fundamental","pubTime":"2026-04-17 22:16","pubTimestamp":1776435363,"startTime":"0","endTime":"0","summary":"BUZZ-Obesity drug developer Kailera on track for Nasdaq debut above offer price** Weight-loss drug developer Kailera Therapeutics KLRA.O on track to open above offer price in Nasdaq debut** Stock recently indicated to open at $32 apiece versus $16 offer price** Waltham, Massachusetts-based KLRA sold 39.1 million shares in an upsized IPO at top end of $14-$16 apiece marketed range to raise $625 million** Demand for weight-loss drugs has sky-rocketed in recent years, with the market expected to generate about $150 billion in annual sales in the next decade** Kailera's lead product candidate ribupatide is in late-stage trials as a once-weekly injectable GLP-1 drug** Obesity, GLP-1 drug developers continue to fetch high takeover premiums, as seen with the recent acquisition of Metsera by Pfizer - IPOX Research Associate Lukas Muehlbauer ** J.P. Morgan, Jefferies, Leerink Partners, TD Cowen, Evercore ISI acted as joint book-running managers for offering  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nL6N4100UX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002232.USD","LU0306807586.USD","SG9999003800.SGD","BK4007","BK4585","IE00BLSP4239.USD","LU0170899867.USD","LU1057294990.SGD","BK4534","LU0058720904.USD","LU1894683348.USD","SG9999001176.SGD","IE00B19Z3581.USD","BK4588","LU1023059063.AUD","LU0225284248.USD","LU0985481810.HKD","IE00BLSP4452.SGD","BK4581","BK4533","LU0321505439.SGD","BK4550","IE00B19Z3B42.SGD","LU1066051498.USD","SG9999002224.SGD","LU0122379950.USD","BK4127","LU1066053197.SGD","SG9999001176.USD","IE000M9KFDE8.USD","LU0456855351.SGD","SG9999013999.USD","KLRA","SGXZ57979304.SGD","BK4207","LU0289739699.SGD","IE00BBT3K403.USD","LU0321505868.SGD","LU0868494617.USD","SG9999011175.SGD","LU0225771236.USD","LU1894683264.USD","LU0306806265.USD","BK4599","IE0002270589.USD","BK4592","BK4568","LU1883839398.USD","LU0234572021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163515964","title":"Weight-Loss Drug Contender Kailera Therapeutics (KLRA.US) Raises $625 Million in Largest US Biotech IPO Since 2021, Set for Nasdaq Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=1163515964","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163515964?lang=en_us&edition=fundamental","pubTime":"2026-04-17 11:38","pubTimestamp":1776397119,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics Inc. (KLRA.US), a clinical-stage biotechnology company focused on obesity treatments, has successfully raised $625 million by increasing the size of its initial public offering....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QQQJ","MNQmain","QLD","BK4539","NVIW.SI","QID","KLRA","TQQQ","QQQ","QQQA","ONEQ","QQQM","SQQQ","TQQY","BK1147","IYW","FTEC","GPIQ","QQQE","BK4007","PSQ","BK4139","QDTE","JEPQ","QQQY","QYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628228877","title":"Kailera Therapeutics 39.06M share IPO priced at $16.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2628228877","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628228877?lang=en_us&edition=fundamental","pubTime":"2026-04-17 08:05","pubTimestamp":1776384337,"startTime":"0","endTime":"0","summary":"The deal size was increased to 39.06M shares from 33.3M and priced at high end of $14.00-$16.00 range. JPMorgan, Jefferies, Leerink, TD Cowen and E...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-39-06m-share-ipo-priced-at-16-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-39-06m-share-ipo-priced-at-16-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPOS","LU1548497426.USD","BK4566","BK4533","IE00BYXW3230.USD","LU0006306889.USD","BK4585","LU0310799852.SGD","LU0943347566.SGD","JPO","LU1720051017.SGD","LU2213496289.HKD","LU2237443465.HKD","LU0496365809.HKD","LU1894683264.USD","LU2456880835.USD","IE00BDCRKT87.USD","KLRA","LU0267386448.USD","LU1244550221.USD","LU1145028129.USD","LU0238689110.USD","LU0070302665.USD","LU0211327993.USD","LU0345770308.USD","BK4534","BK4516","LU2023250843.SGD","LU1894683348.USD","SPCX","LU2756315664.SGD","LU0208291251.USD","LU0417517546.SGD","IE00BLSP4452.SGD","LU1629891620.HKD","LU2054465674.USD","LU2023250330.USD","LU0048584097.USD","LU1064131342.USD","LU0820562030.AUD","LU1551013425.SGD","IE00BLSP4239.USD","LU0149725797.USD","LU0203347892.USD","LU0211331839.USD","JPMO","IE00BWXC8680.SGD","IE00BN8TJ469.HKD","LU2462157665.USD","LU0683600562.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628235247","title":"BRIEF-Kailera Therapeutics Announces Pricing Of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2628235247","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628235247?lang=en_us&edition=fundamental","pubTime":"2026-04-17 07:29","pubTimestamp":1776382157,"startTime":"0","endTime":"0","summary":"BRIEF-Kailera Therapeutics Announces Pricing Of Initial Public OfferingApril 16 (Reuters) - KAILERA THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERINGKAILERA THERAPEUTICS: PRICES INITIAL PUBLIC","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nTUA5MSV9F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628024723","title":"Kailera Therapeutics Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2628024723","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628024723?lang=en_us&edition=fundamental","pubTime":"2026-04-17 07:25","pubTimestamp":1776381900,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., April  16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/16/3275907/0/en/Kailera-Therapeutics-Announces-Pricing-of-Initial-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USA","IPOS","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187752792","title":"Kailera Therapeutics Sets IPO Price Range at $14-$16 Per Share, Aims for Nasdaq Listing This Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1187752792","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187752792?lang=en_us&edition=fundamental","pubTime":"2026-04-14 15:24","pubTimestamp":1776151444,"startTime":"0","endTime":"0","summary":"Clinical-stage biotechnology firm Kailera Therapeutics (KLRA.US), which focuses on developing injectable and oral GLP-1-based treatments for obesity, announced the terms of its initial public...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SQQQ","QQQA","FTEC","BK4539","IYW","QQQJ","NVIW.SI","JEPQ","QYLG","KLRA","BK4007","QQQM","QQQE","ONEQ","PSQ","QQQY","TQQY","BK1147","QID","QDTE","TQQQ","GPIQ","QQQ","MNQmain","QLD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":80,"code":"91000000","status":"200"}]}}